DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Affirm, Disney, Krispy Kreme, TransDigm and more
▼ + stars: | 2023-11-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Affirm posted $496.5 million in revenue, more than the $444.5 million consensus estimate, according to FactSet. It posted adjusted per-share earnings of $8.03, greater than the consensus estimate of $7.55, according to FactSet. The media conglomerate expanded its cost-cutting measures by $2 billion, and reported stronger-than-expected adjusted earnings for the fiscal fourth quarter. Becton, Dickinson and Company — Shares dropped more than 8% after Becton, Dickinson and Company reported disappointing quarterly earnings. The medical technology company posted adjusted earnings of $3.42 per share, lower than the $3.43 per share anticipated by analysts polled by LSEG, formerly Refinitiv.

Persons: Duolingo, Valaris, FactSet, Dickinson, Krispy Kreme, Amylyx, CNBC's Lisa Han, Alex Harring, Hakyung Kim Organizations: . Virgin Galactic Holdings, TransDigm, — Aerospace, TransDigm Group, Disney —, Disney, Barclays, Arm, Company, LSEG, Revenue, AMC Entertainment, Pharmaceuticals

☆ Stocks making the biggest moves premarket: Disney, Lyft, Krispy Kreme and more
▼ + stars: | 2023-11-09 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Virgin Galactic posted a loss of 28 cents per share, versus the 43 cents per share loss expected by analysts polled by LSEG. Krispy Kreme — Shares of the donut maker dropped 4.8% after the company fell short of expectations on earnings and revenue. Krispy Kreme reported earnings of 3 cents per share on revenue of $407 million, while analysts polled by LSEG expected earnings of 6 cents per share on $414 million in revenue. The ridesharing company reported third-quarter bookings of $3.55 billion, lower than the $3.90 billion anticipated by analysts polled by FactSet. Earnings came out at $3.42 per share, while analysts polled by LSEG had called for $3.43 per share in earnings.

Persons: Virgin Galactic, Krispy Kreme, LSEG, Goldman Sachs, FactSet ., —, Bud, Dickinson, Wall, FactSet, CNBC's Hakyung Kim, Jesse Pound, Sarah Min, Lisa Kailai Han Organizations: Galactic, Virgin Galactic, LSEG . Revenue, Virgin, Disney —, Disney, ESPN, —, ISI, Barclays, Apellis Pharmaceuticals, FactSet, Arm, Anheuser, Busch InBev —, HSBC, Busch, Company Locations: U.S

☆ Here are Thursday's biggest analyst calls: Nvidia, Disney, Tesla, Instacart, Arm, Rivian, Target & more
▼ + stars: | 2023-11-09 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Thursday's biggest calls on Wall Street: Goldman Sachs initiates Apellis Pharmaceuticals as buy Goldman initiated the biotech company with a buy and says it sees "continued execution." Bank of America reiterates Disney as buy Bank of America said it's standing by its buy rating after Wednesday's earnings report. Goldman Sachs reiterates Arm as overweight Goldman said it's sticking with its buy rating after the stock's earnings report on Wednesday. Goldman Sachs reiterates Instacart as buy Goldman said it's sticking with its buy rating on the grocery delivery company after Instacart's earnings report on Wednesday. Morgan Stanley reiterates Rivian as overweight Morgan Stanley said it's sticking with its overweight rating on the electric vehicle company. "

Persons: Goldman Sachs, Goldman, Tesla, WK Kellogg, Kellogg, Wolfe, Instacart, Morgan Stanley, Rivian, Eli Lilly, MRK's Keytruda, Evercore, it's bullish, Parker, Wells, it's, Hein Schumacher Organizations: Apellis Pharmaceuticals, HSBC, Tesla, Barclays, JPMorgan, Bank of America, Disney, ARM, Deutsche Bank, Deutsche, Merck, pharma, TAP, Industrial, Nvidia, Anheuser, Busch InBev, Bud, Offshore, Unilever, OW, Citi Locations: North America, Montrose

☆ Stocks making the biggest moves after hours: SolarEdge, Qualcomm, Etsy, Clorox and more
▼ + stars: | 2023-11-01 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

SolarEdge — The solar stock cratered 23% after SolarEdge posted a dismal third-quarter report and outlook for the current quarter's revenue. SolarEdge lost 55 cents per share, excluding items, while analysts polled by LSEG, formerly known as Refinitiv, forecast a gain of 89 cents per share. The company guided revenue for the current quarter to between $300 million and $350 million, well under the $688 million anticipated by analysts. Qualcomm surpassed analysts' estimates in its fiscal fourth quarter, reporting adjusted earnings of $2.02 per share on revenue of $8.67 billion. Etsy beat analysts' estimates for earnings in the third quarter but fell short of Wall Street's expectations on revenue.

Persons: SolarEdge, LSEG, Josh Silverman, Etsy, Roku, Roku's, DoorDash, Clorox, Sarepta, FactSet, Darla Mercado, Sarah Min, Jesse Pound, Scott Schnipper Organizations: LSEG, Revenue, Qualcomm —, Qualcomm, Electronic Arts, Arts, Wall Street, Tandem Diabetes Care, Ritz, Therapeutics Locations: FactSet

☆ Why we're upbeat on chemicals maker DuPont, despite its narrowed guidance
▼ + stars: | 2023-11-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +8 min

But we remain optimistic the specialty chemicals company's electronics business will turn next year, leading to revived growth. At the same time, DuPont raised concerns about its water and safety solutions business due to ongoing destocking and a weaker China. The electronics and industrial segment is comprised of three subunits: semiconductor technologies, interconnect solutions and industrial solutions. Guidance DuPont shaved its full-year net sales outlook to about $12.17 billion, from a previous range of $12.45 billion to $12.55 billion. The company cited additional channel inventory destocking and slow industrial demand in China, mostly in its water solutions business, for its revised guidance.

Persons: Ed Breen, DuPont, Jim Cramer's, Jim Cramer, Jim, Edward Breen, Brendan McDermid Organizations: DuPont de Nemours, DuPont, Spectrum Plastics, CNBC, New York Stock Exchange Locations: China

☆ Stocks making the biggest moves midday: SoFi, McDonald's, Western Digital, On Semiconductor and more
▼ + stars: | 2023-10-30 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

SoFi Technologies — Shares seesawed as traders digested the company's latest quarterly results. McDonald's — Shares gained 2.3% after the company beat both top and bottom lines for the third quarter. Western Digital — Shares of the data storage company jumped 6% after the company performed better than analysts polled by LSEG expected in the fiscal first quarter. Invitation Homes — The home leasing company rose nearly 1% following an upgrade to outperform by Oppenheimer. Saia — The transportation stock rose 3.4% on the back of an upgrade to outperform from peer perform by Wolfe Research.

Persons: SoFi, originations, McDonald's, Stellantis, LSEG, Revvity, FactSet, Oppenheimer, L3Harris, Raymond James, Eastman, AbbVie, Tesla, Bernstein, TD Cowen, —, Femsa, Saia, Jesse Pound, Samantha Subin, Pia Singh, Hakyung Kim, Justin Sullivan Organizations: General Motors, GM, CNBC, Ford, Spirit Realty Capital, Realty, Western Digital, Semiconductor, FactSet, Eastman Chemical —, JPMorgan, Barclays, Citi, Wolfe Research, SoFi Technologies Locations: U.S, San Francisco , California

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

☆ Top Wall Street analysts favor these five dividend stocks during tumultuous times
▼ + stars: | 2023-10-22 | by ( Tipranks.Com Staff | ) www.cnbc.com time to read: +7 min

The company paid a dividend of $1.74 per share in late September, which included a quarterly base dividend of 50 cents per share and a variable dividend of $1.24. The acquisition, anticipated to close in January 2024, is expected to boost CIVI's free cash flow per share by 5% in 2024. In September, the company announced a quarterly dividend of 57 cents per share, payable on Nov. 1. (See Chesapeake Insider Trading Activity on TipRanks)EOG ResourcesLet's look at another energy company: EOG Resources (EOG). Based on this quarterly dividend, the annual dividend rate comes to $3.30 per share, bringing the dividend yield to 2.5%.

Persons: Paresh Dave, Wall, Civitas, Lloyd Byrne, CIVI, Byrne, TipRanks, Bristol Myers, BMY, Goldman Sachs, Chris Shibutani, Shibutani, Umang Choudhary, Choudhary, EOG, Nitin Kumar, Eagle, Kumar Organizations: Cisco Systems Inc, Civitas, Civitas Resources, Vencer Energy, Jefferies, Midland, Bristol, Bristol Myers Squibb, Mirati Therapeutics, Chesapeake Energy, Management, Chesapeake, EOG, Eagle Ford, TipRanks, Cisco Locations: San Jose , California, Denver, Midland, West Texas

☆ Stocks making the biggest moves midday: SolarEdge, Regions Financial, Merck and more
▼ + stars: | 2023-10-20 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Schlumberger — The oilfield services stock dropped 2.9% after third-quarter revenue missed Wall Street expectations. Revenue came in at $15.38 billion, versus the $15.36 billion expected. Late Thursday, SolarEdge slashed guidance for third-quarter revenue, gross margin and operating income. Net interest also fell short at $1.29 billion, versus the $1.32 billion expected. Revenue came in at $1.74 billion, versus the $1.77 billion expected from analysts polled by LSEG.

Persons: Schlumberger, SolarEdge, Sunnova, Sunrun, KeyCorp, Swift, David Jackson, —, Alex Harring, Samantha Subin, Hakyung Kim, Michelle Fox Organizations: Schlumberger, LSEG, American, American Express, LSEG . Revenue, Merck — Merck, UBS, Enphase Energy, StreetAccount, Comerica, Swift, Revenue Locations: Zions

☆ Stocks making the biggest moves after hours: United Airlines, J.B. Hunt, Interactive Brokers and more
▼ + stars: | 2023-10-17 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

United Airlines said it expects adjusted earnings to range between $1.50 and $1.80 per share, versus the $2.06 per share expected by analysts polled by LSEG, formerly known as Refinitiv. For the recent quarter, the company topped Wall Street's expectations, reporting adjusted earnings of $3.65 per share on $14.48 billion in revenue. J.B. Hunt Transport Services — The transportation and logistics stock lost 2% after reporting third-quarter results that fell short of Wall Street's expectations. J.B. Hunt posted earnings of $1.80 per share, versus the $1.84 per share expected by analysts surveyed by LSEG. Interactive Brokers posted third-quarter adjusted earnings of $1.55 per share on adjusted revenue of $1.14 billion.

Persons: J.B, Hunt, Omnicom, FactSet, LSEG, —, Darla Mercado Organizations: United Airlines —, United Airlines, LSEG, Hunt Transport Services, LSEG . Revenue, Interactive, Viking Therapeutics Locations: Tel Aviv, Israel

☆ Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump
▼ + stars: | 2023-10-13 | by ( Jacob Pramuk | ) www.cnbc.com time to read: +1 min

Pfizer slashed its full-year earnings and revenue guidance on Friday, as it said demand for its Covid products has waned. The company now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion. Pfizer said it cut its revenue outlook "solely due to its Covid products." The biopharmaceutical company slashed its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share, from a previous $3.25 to $3.45 per share. It also said it anticipates sales of its vaccine, Comirnaty, will be $2 billion lower than previously expected because of lower-than-expected vaccination rates.

Persons: Albert Bourla Organizations: Pfizer, European Commission, BioNTech, U.S ., CNBC, YouTube Locations: U.S, Puurs, Belgium

☆ Here’s why this under-the-radar biopharma stock could leap nearly 140%, Goldman Sachs says
▼ + stars: | 2023-10-11 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

An overly negative reception to clinical results could mean investors are missing out on potential upside for Syndax Pharmaceuticals , according to Goldman Sachs. The investment bank initiated coverage of the biopharmaceutical company on Wednesday with a buy rating, setting a 12-month price target of $30. This implies potential upside of 137% from the stock's Tuesday closing price of $12.65. In its Oct. 2 announcement, Syndax said it had "positive topline data" from the protocol-defined pooled analysis of this trial. "Based on our analysis and view, we believe the stock is currently trading below the value of near-term commercial opportunities ex-cash/-terminal value," he wrote.

Persons: Goldman Sachs, Syndax, Chris Shibutani, Shibutani, — CNBC's Michael Bloom Organizations: Syndax Pharmaceuticals Locations: 2024E

☆ JPMorgan says controversial eye disease treatment can more than double this biopharma stock
▼ + stars: | 2023-10-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

A controversial eye treatment from Apellis can lead to sharp returns for investors, according to JPMorgan. The bank upgraded the biopharmaceutical stock to overweight from neutral and raised its price target to $81 from $60. The drug aims to treat an eye disease called geographic atrophy, which, according to the Syfovre website, affects about 1 million people. APLS YTD mountain Apellis ytd chart Analyst Anupam Rama believes that Apellis' overall pipeline has only been strengthened by recent approvals of Syfovre. The analyst noted that some physicians who had initially paused treatment of Syfovre have already begun to return to prescribing the injection.

Persons: Anupam Rama, Apellis, Rama, Michael Bloom Organizations: JPMorgan, ~$ Locations: 4Q

☆ Stocks making the biggest premarket moves: Pioneer Natural Resources, Levi Strauss, Tesla, Philips and more
▼ + stars: | 2023-10-06 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Check out the companies making the biggest moves in premarket trading:Pioneer Natural Resources — The energy stock soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Levi Strauss — The denim apparel maker shed 1.3% after cutting its full-year sales forecast. Apellis Pharmaceuticals — Shares of the biopharmaceutical company rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. Aehr Test Systems — Shares fell more than 11% despite Aehr Test Systems reporting an earnings and revenue beat for its first quarter. Frontline — The shipping stock shed 4.8% in premarket trading after Euronav said its second shareholder, Compagnie Maritime Belge, would acquire Frontline's shares in Euronav for $18.43 per share.

Persons: Levi Strauss, Philips —, ResMed, Tesla, Euronav, Macheel, Jesse Pound Organizations: Resources, Street Journal, Exxon Mobil, Exxon, Philips, U.S . Food, Drug Administration, FDA, U.S, Apellis Pharmaceuticals, JPMorgan, Aehr, Systems, Compagnie Maritime Belge Locations: Dutch, U.S, Euronav

Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that's in the business of water quality. When we receive Veralto shares on Monday, as all Danaher shareholders will, we intend to keep them, based on their current expected value. A "when-issued" market was established Wednesday for both Danaher and Veralto stock, providing a first look at how investors are valuing the companies on their own. Investors will receive one share in Veralto for every three shares of Danaher they own. The caveat is that spin-off debuts can see substantial volatility, and if Veralto shares were to receive a big pop, our discipline may require us to capitalize on that and take profits.

Persons: it's, Danaher, Jim Cramer, Jim Cramer's, Veralto, we'll, –, disinfect, That's, we've, attractively, We're, Jim, Pavlo Gonchar Organizations: Deutsche Bank, Zebra Technologies, CNBC, Getty Locations: Veralto, Danaher, DHR, Wells, York

☆ Morgan Stanley names the global stocks set to be 'disadvantaged' from rising yields
▼ + stars: | 2023-09-28 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +2 min

The U.S. Federal Reserve struck a hawkish tone at its latest meeting and Treasurys have risen to multi-year highs . According to Morgan Stanley, those conditions could put certain stocks in Asian and emerging markets at a disadvantage. "We believe large cap growth stocks, particularly the low quality and unprofitable ones, could come under pressure," they said. More specifically, those set to be "disadvantaged" are high-growth names "with low balance sheet quality" and low free cash flow yield. Morgan Stanley had an underweight rating for Alibaba Health Information Technology , a Chinese integrated pharmaceutical services provider.

Persons: Morgan Stanley, Meituan, Xero, CNBC's Michael Bloom Organizations: U.S . Federal Reserve, Sony, Hong, New, Nio, HK, Alibaba Health, Technology Locations: U.S, Hong Kong, New Zealand

☆ Stocks making the biggest moves midday: General Motors, Stellantis, Planet Fitness, Adobe and more
▼ + stars: | 2023-09-15 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Nucor — The steelmaker fell 6.1% after offering worse-than-expected guidance for third-quarter earnings, with the company pointing to pricing and volume challenges. Core & Main — The infrastructure stock retreated 4.1% a day after it announced a secondary stock offering. The bank said Apellis has a favorable risk/reward ahead of third-quarter earnings. The Wall Street firm said the resumption of loan repayments introduce bookings risk to food delivery. The Wall Street firm said its pessimistic outlook was changing despite recent underperformance in the reinsurance space.

Persons: Stellantis, Chris Rondeau, Rondeau, Craig Benson, Nucor, Raymond James, Needham, Charles Shi, Lam, Goldman Sachs, Apellis, MoffettNathanson, Estée Lauder, Goldman, Yun Li, Jesse Pound, Samantha Subin, Pia Singh, Brian Evans, Lisa Kailai Han Organizations: UAW, General Motors Wentzville, General Motors, Ford, United Auto Workers began, Workers, CNBC, LSEG, PTC Therapeutics, Medicines Agency's, Medicinal Products, Arm, Investment, Bloomberg News, Apple, Dexcom, ASML Holding, Lam Research, Taiwan Semiconductor, Adobe, Bank of America, JPMorgan, Apellis Pharmaceuticals, Waste Systems Locations: Wentzville , Missouri, New Hampshire, Wells, underperform

☆ Stocks making the biggest moves premarket: Arm Holdings, GM, Ford, Adobe and more
▼ + stars: | 2023-09-15 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

General Motors assembly workers picket outside the General Motors Bowling Green plant during the United Auto Workers national strike in Bowling Green, Kentucky, October 10, 2019. Apellis Pharmaceuticals — The biopharmaceutical company climbed 3.5% before the open after Wells Fargo upgraded to overweight from equal weight. General Motors , Ford , Stellantis — GM and Ford fell less than 1% and Stellantis rose less than 1% after the United Auto Workers went on strike Thursday night. DoorDash — Shares of the food delivery company slid almost 3% premarket after MoffettNathanson downgraded DoorDash to market perform from outperform. Adobe — Shares fell 3.4% on the back of the company's fiscal third-quarter earnings report Thursday.

Persons: —, Piper Sandler, Piper, Morgan Stanley, Wells, Apellis, Stellantis, MoffettNathanson, Needham, Goldman Sachs, — CNBC's Brian Evans, Michelle Fox, Alex Harring, Hakyung Kim, Tanaya Macheel, Jesse Pound, Pia Singh Organizations: Motors, General Motors, United Auto Workers national, Pharmaceuticals, Ford, United Auto Workers, Unity, Bank of America, Arm, Nasdaq, JPMorgan, LSEG Locations: Bowling Green , Kentucky, — The Cleveland, DoorDash, British

Sept 11 (Reuters) - Klaviyo is seeking a fully-diluted valuation of up to $8.4 billion in its initial public offering (IPO) in the United States, the marketing firm said on Monday, as it becomes the latest company to tap a growing wave of stock market listings. However, the company's proposed valuation is a climb-down from the $9.15 billion pre-money valuation at which Klaviyo last raised capital in 2021, reflecting a broader gloom in the technology startup ecosystem. Founded in 2012, Klaviyo helps store and analyze data for e-commerce brands that enables them to send out personalized marketing emails and messages to potential customers. Klaviyo posted 51% growth in revenue to $164.6 million for the three months ended June 30. The company is expected to debut in September, a busy month for stock market listings that could serve as a litmus test for other companies looking to go public.

Persons: Andrew Bialecki, Klaviyo, AllianceBernstein, Goldman Sachs, Morgan Stanley, Sri Hari, Manya, Niket Nishant, Shweta Agarwal, Maju Samuel Organizations: Arm Holdings, Neumora Therapeutics, Summit Partners, BlackRock, New York Stock Exchange, Citigroup, underwriters, Sri, Manya Saini, Thomson Locations: United States, Boston, United Kingdom, Australia, Bengaluru

☆ Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
▼ + stars: | 2023-09-08 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The biopharmaceutical sector is poised to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95, which suggests shares stand to gain 28.5% from where they closed Thursday. Shares of California-based Gilead have dropped 13.9% so far this year. "With the potential for broader interest in the sector, we are more optimistic on performance into 2H23," Meacham said.

Persons: Geoff Meacham, Meacham, biopharma, — Michael Bloom Organizations: Gilead Sciences, Bank of America, PrEP, Kite Pharma Locations: Gilead, California, HCV

☆ Here are the most overbought and oversold major global stocks, including tech and banking names
▼ + stars: | 2023-09-06 | by ( Weizhen Tan | ) www.cnbc.com time to read: +1 min

Global stocks, too, were bumpy last month: The MSCI World index fell in the middle of the month before paring some losses toward the end. The relative strength index (RSI), which measures the magnitude and speed of price moves, can be used by investors to determine if shares are overbought or oversold. CNBC Pro screened the MSCI World index for major global stocks that are among the most overbought and oversold, based on their 14-day RSI. Oversold names These names are among the most oversold global stocks, spanning health care, autos and banking. Overbought names These names are among the most oversold global stocks, including some in the tech sector.

Persons: It's, Johnson, Japan's, BYD Organizations: CNBC Pro, Global, Volkswagen, BMW, CVS Health, Johnson, UnitedHealth Group, IBM, Dell, Cisco, Horizon Therapeutics Locations: U.S

☆ Nestle divests peanut allergy business Palforzia
▼ + stars: | 2023-09-04 | by ( ) www.reuters.com time to read: +1 min

Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics, based in Brisbane, California, in this handout obtained by Reuters on February 5, 2020. Aimmune Therapeutics/Handout via REUTERS/File Photo Acquire Licensing RightsZURICH, Sept 4 (Reuters) - Nestle (NESN.S) has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division. Nestle said it has offloaded Palforzia to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer, it said. Reporting by John Revill, Editing by Friederike HeineOur Standards: The Thomson Reuters Trust Principles.

Persons: Nestle, Stallergenes Greer, John Revill, Friederike Heine Our Organizations: Aimmune Therapeutics, Reuters, REUTERS, Rights, Nestle, Thomson Locations: Brisbane , California, Swiss

☆ Here are Tuesday's biggest analyst calls: Disney, Nvidia, Ford, Walmart, JPMorgan, Palo Alto and more
▼ + stars: | 2023-08-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Daiwa reiterates Disney as buy Daiwa is standing by its buy rating on Disney after the company's earnings report last week. Deutsche Bank reiterates Palo Alto Networks as buy Deutsche Bank is bullish heading into earnings later this week. Barclays reiterates Walmart as overweight Barclays is bullish heading into earnings later this week. " Bank of America downgrades Phillips 66 and Marathon Petroleum to neutral from buy Bank of America downgraded several refiners and said the risk/reward is "no longer compelling." Bank of America initiates Turnstone Biologics as buy Bank of America said the biopharmaceutical company is well-positioned.

Persons: it's, Daiwa, KBW, Berkshire Hathaway, Morgan Stanley, Pharvaris, Wells Fargo, Wells, it's bullish, Hannon Armstrong, KeyBanc, PSTG, " Bank of America downgrades Phillips, DINO, Ford Organizations: UBS, Nvidia, Disney, Deutsche Bank, Networks, JPMorgan, Citigroup, Bank of America, ISI, Barclays, Walmart, " Bank of America, of America, Marathon Petroleum, U.S, MPC, Ford

☆ Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and more
▼ + stars: | 2023-08-08 | by ( Brian Evans | ) www.cnbc.com time to read: +4 min

The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. Palantir Technologies — Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Beyond Meat reported an adjusted loss of 83 cents per share on $102.1 million in revenue, while Refinitiv forecasted 86 cents and $108.4 million. Paramount Global — The media conglomerate's shares climbed more than 2% in premarket trading after the company reported a quarterly earnings and revenue beat.

Persons: Goldman Sachs, NASH, Banks, Moody's, Eli Lilly, EchoStar, Charlie Ergen, Refinitiv, Lucid, Palantir, Hims, Simon & Schuster, Yun Li, Samantha Subin, Sarah Min, Pia Singh, Jesse Pound Organizations: Sagimet, Goldman, T Bank, Citizens Financial, Bank of New York Mellon, Truist, JPMorgan Chase, Telsey, Refinitiv, Novo Nordisk —, Dish, United Parcel Service, behemoth, UPS, Palantir, Paramount Global, Paramount, KKR Locations: New York, Banks —

☆ Goldman says this little-known biotech stock could more than double
▼ + stars: | 2023-08-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Clinical-stage biopharmaceutical company Sagimet Biosciences could see its treatments reach a breakout stage, which could send its share price soaring, according to Goldman Sachs. The stock has been publicly traded since July 14, and it's trading slightly below its IPO level. Investors are focused on upcoming biopsy results of the second phase of the denifanstat study on liver fat levels, said Tan. Positive results from this phase would support advancement into a pivotal phase three study, she added. The "role of FASN in other indications could offer upside," Tan noted.

Persons: Goldman Sachs, NASH, Andrea Tan, Tan, Denifanstat, FASN, — CNBC's Michael Bloom Organizations: Sagimet Biosciences

Search resuls for: "Biopharmaceutical"

25 mentions found